Chromogranin A is a T cell antigen in human type 1 diabetes

Author
Peter Gottlieb, Thomas Delong, Rocky Baker, Lisa Fitzgerald-Miller, Rebecca Wagner, Gabrielle Cook, Marian Rewers, Aaron Michels, Kathryn Haskins
Keywords
Abstract

<p>Chromogranin A (ChgA) is a beta cell secretory granule protein and a peptide of ChgA, WE14, was recently identified as a ligand for diabetogenic CD4 T cell clones derived from the NOD mouse. In this study we compared responses of human CD4 T cells from recent onset type 1 diabetic (T1D) and control subjects to WE14 and to an enzymatically modified version of this peptide. T cell responders to antigens were detected in PBMCs from study subjects by an indirect CD4 ELISPOT assay for IFN-γ. T1D patients (n = 27) were recent onset patients within one year of diagnosis, typed for HLA-DQ8. Controls (n = 31) were either 1st degree relatives with no antibodies or from the HLA-matched general population cohort of DAISY/TEDDY. A second cohort of patients (n = 11) and control subjects (n = 11) was tested at lower peptide concentrations. We found that WE14 is recognized by T cells from diabetic subjects vs. controls in a dose dependent manner. Treatment of WE14 with transglutaminase increased reactivity to the peptide in some patients. This work suggests that ChgA is an important target antigen in human T1D subjects and that post-translational modification may play a role in its reactivity and relationship to disease.</p>

Year of Publication
2014
Journal
Journal of autoimmunity
Volume
50
Number of Pages
38-41
Date Published
05/2014
ISSN Number
1095-9157
DOI
10.1016/j.jaut.2013.10.003
Alternate Journal
J Autoimmun
PMCID
PMC3995825
PMID
24239002
Download citation
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ